Cutaneous leishmaniasis: Current and future management

Expert Review of Anti-Infective Therapy

Volumn 1, Issue 4, 2003, Pages 563-570

  Hepburn, Neill C ^a  

^a LINCOLN COUNTY HOSPITAL   (United Kingdom)

Author keywords

Cutaneous leishmaniasis; Imiquimod; Pentavalent antimonials; Topical treatment

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; IMIQUIMOD; KETOCONAZOLE; LIQUID NITROGEN; MEGLUMINE ANTIMONATE; MILTEFOSINE; MONOCLONAL ANTIBODY; PAROMOMYCIN; PENTAMIDINE; POTASSIUM; PYRROLE DERIVATIVE; STIBOGLUCONATE SODIUM;

ANAMNESIS; ANOREXIA; ANTIBODY DETECTION; ARTHRALGIA; CHILL; CLIMATE CHANGE; CLINICAL FEATURE; CLINICAL TRIAL; CRYOTHERAPY; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DIARRHEA; DOSE RESPONSE; DRUG MECHANISM; ENVIRONMENTAL FACTOR; FEVER; HEART ARREST; HUMAN; HYPOGLYCEMIA; HYPOKALEMIA; IMMUNOTHERAPY; INCIDENCE; LEISHMANIA; MALAISE; MOTION SICKNESS; MYALGIA; NEPHROTOXICITY; PATHOPHYSIOLOGY; PUBLIC HEALTH; REVIEW; SKIN BIOPSY; SKIN IRRITATION; SKIN LEISHMANIASIS; TACHYCARDIA; TISSUE CULTURE; VOMITING;

EID: 3042781116     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.1.4.563     Document Type: Review

References (63)

1. Herwaldt BL. Leishmaniasis. Lancet 354, 1191-1199 (1999).
2. Davies CR, Kaye P, Croft SL, Sundar S. Leishmaniasis: new approaches to disease control. Br. Med. J. 326, 377-382 (2003).
3. Gilles HM (Ed). Protozoal Diseases. Arnold, London, UK (1999).
4. Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM. Post-kala-azar dermal leishmaniasis. Lancet Infect. Dis. 3, 87-98 (2003).
5. Ashford RW, Desjeux P, de Raadt P. Estimation of population at risk of infection and number of cases of leishmaniasis. Parasitol. Today 8, 104-105 (1992).
6. Gonzalez R, De Sousa L, Devera R, Jorquera A, Ledezema E. Seasonal and nocturnal domiciliary human landing/biting behaviour of Lutzomyia (lutzomyia) evansi and Lutzomyia (Psychodopygus) panamensis (diptera; Psychodidae) in a periurban area of a city on the Caribbean coast of eastern Venezuela (Barcelona; Anzoategui State). Trans. R. Soc. Trop. Med. Hyg. 93, 361-364 (1999).
7. Tayeh A, Jalouk L, Cairncross S. Twenty years of cutaneous leishmaniasis in Aleppo, Syria. Trans. R. Soc. Trop. Med. Hyg. 91, 657-659 (1997).
8. Brandao-Filho SP, Campbell-Lendrum D, Brito ME, Shaw JJ, Davies CR. Epidemiological surveys confirm an increasing burden of cutaneous leishmaniasis in north-eastern Brazil. Trans. R. Soc. Trop. Med. Hyg. 93, 488-494 (1999).
9. Weigle KA, Valderrama L, Arias AL, Santrica C, Saravia NG. Leishmanin standardization and evaluation of safety, dose, storage, longevity of reaction and sensitization. Am. J. Trop. Med. Hyg. 44, 260-271 (1991).
10. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans. R. Soc. Trop. Med. Hyg. 95, 239-243 (2001).
11. Rosenthal E, Marty P, Poizot-Martin I et al. Visceral leishmaniasis and HIV-1 coinfection in southern France. Trans. R. Soc. Trop. Med. Hyg. 89, 159-162 (1995).
12. Ara M, Maillo C, Peon G, Clavel A et al. Visceral leishmaniasis with cutaneous lesions in a patient infected with human immunodeficiency virus. Br. J. Dermatol. 139, 114-117 (1998).
13. Paredes R, Munoz J, Diaz I, Domingo P, Gurgui M, Clotet B. Leishmaniasis in HIV Infection. J. Postgrad. Med. 49, 39-49 (2003).
14. Herwaldt BI, Stokes SL, Juranek DD. American cutaneous leishmaniasis in US travelers. Ann. Intern. Med. 118, 779-784 (1993).
15. Magill AJ, Grogl M, Gasser RA, Sun W, Oster CN. Visceral infection caused by Leishmania tropica in veterans of Operation Dessert Storm. N. Engl. J. Med. 328, 1383-1387 (1993).
16. Kubba R, Al-Gindan Y. Leishmaniasis. Dermatol. Clinics 7, 331-351 (1989).
17. Croft S, Yardley V. Chemotherapy of leishmaniasis. Curr. Pharm. Des. 8, 319-342 (2002).
18. Kalter DC. Cutaneous and mucocutaneous leishmaniasis. Program. Derm. 23, 1-11 (1989).
19. Lever WF, Schamberg-Lever G. Histopathology of the Skin (Seventh Edition). Lippincott, PA, USA (1990).
20. Hepburn NC, Tidman MJ, Hunter JAA. Cutaneous lashmaniasis in British troops from Belize. Br. J. Dermatol. 128, 63-68 (1993).
21. Barral A, Guerreiro J, Bomfim D, Correia M, Barral-Netto M, Carvalho EM. Lymphadenopathy as the first sign of human cutaneous infection by Leishmania baziliensis. Am. J. Trop. Med. Hyg. 53, 256-259 (1995).
22. Bryceson A. Therapy in man. In: The Leishmaniasis in Biology and Medicine. Peters W, Killick-Kendrick R (Eds). Academic Press, London, UK 847-907 (1987).
23. Herwaldt BL, Arana BA, Navin TR. The natural history of cutaneous leishmaniasis in Guatemala. J. Infect. Dis. 165, 518-527 (1992).
24. Locksley RM, Louis JA. Immunology of leishmaniasis. Curr. Opin. Immunol. 4, 413-418 (1992).
25. Kubba R, Al-Gindan Y, El-Hassan AM, Omer AHS. Clinical diagnosis of cutaneous leishmaniasis (oriental sore). J. Am. Acad. Derm. 16, 1183-1189 (1987).
26. Navin TR, Arana FE, de Merida M, Avana BA, Castillo AL, Silvers DN. Cutaneous leishmaniasis in Guatemala: comparison of diagnostic methods. Am. J. Trop. Med. Hyg. 42, 36-42 (1990).
27. Herwaldt BL, Arana FE, Navin TR. The natural history of cutaneous leishmaniasis in Guatemala. J. Infect. Dis. 165, 518-527 (1992).
28. Robinson RJ, Agudelo S, Muskus C et al. The method used to sample ulcers influences the diagnosis of cutaneous leishmamasis. Trans. R. Soc. Trop. Med. Hyg. 96, S169-S171 (2002).
29. Evans D. Handbook on Isolation, Characterisation and Cryopreservation of Leishmania. UNDP/World Bank/WHO(TDR), Geneva, Switzerland (1989).
30. Biddlestone LF, Hepburn NC, McLaren KM. A clinico-pathological study of cutaneous leishmaniasis in British troops from Belize. Trans. R. Soc. Trop. Med. Hyg. 88, 672-676 (1994).
31. Romero GAS, Guerra MVF, Paes MG. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V) guyanensis in Brazil: clinical finding and diagnostic approach. CID 32, 1304-1312 (2001).
32. Andresen K, Gaafar A, El-Hassan AM et al. Evaluation of the polymerase chain reaction in the diagnosis of cutaneous leishmaniasis due to Leishmania major: a comparison with direct microscopy of smears and sections from lesions. Trans. R. Soc. Trop. Med. Hyg. 90, 133-135 (1996).
33. Weigle KA, Labrada LA, Lozano C, Santrich C, Barker DC. PCR-based diagnosis of acute and chronic cutaneous leishmaniasis caused by Leishmania (Viannia). J. Clin. Microbiol. 40, 601-606 (2002).
34. Safaei A, Motazedian MH, Vasei M. Polymerase chain reaction for diagnosis of cutaneous leishmaniasis in histologically positive, suspicious and negative skin biopsies. Dermatology 205, 18-24 (2002).
35. Romero GA, Guerra MV, Paes MG et al. Sensitivity of the polymersase chain reaction for the diagnosis of cutaneous leishmansiasis due to Leishmanis (Viannia) guyanensis. Acta Trop. 79, 225-229 (2001).
36. Isaza DM, Arbola M, Restrepo M, McCann SH, Barker DC. Validation of the polymerase chain reaction for the diagnosis of human cutaneous leishmaniasis in northwest Colombia. Trans. R. Soc. Trop. Med. Hyg. 96, S165-S168 (2002).
37. Mimori T, Matsumoto T, Calvopina MH, Gomez EA et al. Usefulness of sampling with cotton swab for PCT-diagnosis of cutaneous leishmaniasis in the New World. Acta Trop. 81, 197-202 (2002).
38. Navin TR, Arana FE, Berman JD, Chajon JF. Placebo-controlled clinical trial of sodium stibogluconate (pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. JID 165, 528-534 (1992).
39. Lainson R, Shaw JJ. Evolution, Classification and Geographical Distribution. In: The leishmaniases in biology and medecine (volume 1). Peters W, Killick-Kendrick R (Eds). Academic Press, London, UK (1987).
40. WHO. Control of the leishmaniases. Technical report series 793. WHO, Geneva, Switzerland (1990).
41. Uzun S, Uslular C, Yucel A, Acar MA, Ozpoyraz M, Memisoglu HR. Cutaneous leishmaniasis: evaluation of 3074 cases in the Cukurova. region of Turkey. Br. J. Derm. 140, 347-350 (1999).
42. Romero GA, Guerra MV, Paes MG, Macedo VO. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V) guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am. J. Trop. Med. Hyg. 65, 456-465 (2001).
43. Berman JD. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy and future strategies. Rev. Infect. Dis. 10, 560-586 (1988).
44. Hepburn NC, Tidman MJ, Hunter JAA. Aminosidine versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. 88, 700-703 (1994).
45. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (pentostam) and review of pertinent clinical studies. Am. J. Trop. Med. Hyg. 46, 296-306 (1992).
46. El-On J, Jacobs GP, Witztum E, Greenblatt CL. Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals. Antimicrob. Agents Chemother. 26, 745-751 (1984).
47. El-On J, Halevy S, Grunwald MH, Weirauch L. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major a double-blind control study. J. Am. Acad. Dermatol. 27, 227-231 (1992).
48. Bryceson AD. Occlusive paromomycin for cutaneous leishmaniasis. Lancet 349, 1477 (1997).
49. Neal RA, Murphy AG, Olliaro P, Croft SL. Aminosidine ointments for the treatment of experimental cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 88, 223-225 (1994).
50. Bryceson AD, Murphy A, Moody AH. Treatment of 'Old World' cutaneous leishmaniasis with aminosidine ointment: results of an open label study in London. Trans. R. Soc. Trop. Med. Hyg. 88, 226-228 (1994).
51. Soto J, Toledo J, Gutierrez P et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin. Infect. Dis. 33, E5-E61 (2001).
52. Soto J, Grogl M, Berman J, Olliaro, P. Limited efficacy of injectable aminosidine as single-agent therapy for Colombian cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 88, 695-698 (1994).
53. Berman JD. Human leishmaniasis: clinical, diagnostic and chemotherapeutic developments in the last 10 years. CID 24, 684-703 (1997).
54. Davidson RN, Di Martino L, Gradoni L, Giacchino R, Russo R, Gaeta G et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q. J. Med. 87, 75-81 (1994).
55. New RR, Chance ML, Heath S. Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J. Antimicrob. Chemother. 8, 371-381 (1981).
56. Sampaio RN, Marsden PD. Treatment of the mucosal form of leishmaniasis without response to glucantime, with liposomal amphotericin B. Rev. Soc. Bras. Med. Trop. 30, 125-128 (1997).
57. Vardy D, Barenholz Y, Cohen R et al. Topical amphotericin B for cutaneous leishmaniasis. Arch. Dermatol. 135, 856-857 (1999).
58. Momeni AZ, Aminjavaheri M, Omidghaemi MR. Treatment of cutaneous leishmaniasis with ketoconazole cream. J. Dermatol. Treat. 14, 26-29 (2003).
59. Sundar S, Rosenkaimer F, Makharia MK et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet 352, 1821-1823 (1998).
60. Jha TK, Sundar S, Thakur CP et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N. Engl. J. Med. 341, 1795-1800 (1999).
61. Sundar S, Gupta LB, Makharia MK et al. Oral treatment of visceral leishmaniasis with miltefosine. Ann. Trop. Med. Parasitol. 93, 589-597 (1999).
62. Convit J, Castellanos PL, Rondon A et al. Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis. Lancet 1, 401-405 (1987).
63. Arevalo I, Ward B, Miller R et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin. Infect. Dis. 33, 1847-1851 (2001).